A botulinum toxin A treatment algorithm for de novo management of torticollis and laterocollis

BMJ Open

Volumn 1, Issue 2, 2011, Pages

  Hefter, Harald ^a   Kupsch, Andreas ^b   Müngersdorf, Martina ^c   Paus, Sebastian ^d   Stenner, Andrea ^e   Jost, Wolfgang ^f  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Neurologie am Hackeschen Markt   (Germany)

^d UNIVERSITY OF BONN   (Germany)

^e Paracelsus Klinik   (Germany)

^f DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053518205     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2011-000196     Document Type: Article

References (12)

1. Van Zandijcke M. Cervical dystonia (spasmodic torticollis). Some aspects of the natural history. Acta Neurol Belg 1995;95:210-15.
2. Reichel G, Stenner A, Jahn A. Zur Phänomenologie der zervikalen Dystonien [The phenomenology of cervical dystonia]. Fortschr Neurol Psychiatr 2009;77:272-7.
3. Simpson DM, Blitzer A, Brashear A, et al. Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008;70:1699-706. (Pubitemid 351644138)
4. Poewe W, Deuschl G, Nebe A, et al. What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 1998;64:13-17. (Pubitemid 28156531)
5. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 2005;20:783-91. (Pubitemid 41227144)
6. Truong D, Brodsky M, Lew M, et al. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 2010;16:316-23.
7. Wissel J, Kanovsky P, Ruzicka E, et al. Efficacy and safety of a standardised 500 unit dose of Dysport (Clostridium botulinum toxin type A haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, doubleblind, placebo-controlled, parallel group study. J Neurol 2001;248:1073-8. (Pubitemid 34134544)
8. Walker FO. Botulinum toxin therapy for cervical dystonia. Phys Med Rehabil Clin N Am 2003;14:749-66. (Pubitemid 37243719)
9. Tsui JK, Eisen A, Stoessl AJ, et al. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 1986;2:245-7.
10. Mohammadi B, Buhr N, Bigalke H, et al. A long-term follow-up of botulinum toxin A in cervical dystonia. Neurol Res 2009;31:463-6.
11. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev 2005:CD003633.
12. Brin MF, Comella CL, Jankovic J, et al. Long-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay. Mov Disord 2008;23:1353-60.